PEN Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Penumbra Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 208.55 USD 1.21%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast PEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PEN is 282.93 USD with a low forecast of 242.4 USD and a high forecast of 336 USD.

PEN Lowest Forecast

Wall Street Target

PEN Average Forecast

Wall Street Target

PEN Highest Forecast

Wall Street Target

16% Upside

36% Upside

61% Upside

The latest public price target was made on Aug 2, 2023 by Richard Newitter from Truist Financial , who expects PEN stock to rise by 65% over the next 12 months. You can read more about this price target by viewing the article on Benzinga.

Analyst	Price Target	Date	Article
Richard Newitter Truist Financial	345 USD Upside 65%	9 months ago Aug 2, 2023	Potential For Accelerated Growth In Penumbra Despite Product Launch Delays: Analysts' Positive Outlook Post Q2 Results Benzinga
Unknown Analyst Deutsche Bank	297 USD Upside 42%	1 year ago Feb 7, 2023	Deutsche Bank Maintains Buy on Penumbra, Raises Price Target to $297 Benzinga
Unknown Analyst J.P. Morgan	285 USD Upside 37%	1 year ago Feb 1, 2023	JP Morgan Maintains Overweight on Penumbra, Raises Price Target to $285 Benzinga

Price Target	345 USD
Upside/Downside	65%

Price Target	297 USD
Upside/Downside	42%

Price Target	285 USD
Upside/Downside	37%

Boston Scientific Corp

14% Upside

Fisher & Paykel Healthcare Corporation Ltd

13% Downside

Beijing Wandong Medical Technology Co Ltd

5% Downside

Shanghai United Imaging Healthcare Co Ltd

18% Upside

Boston Scientific Corp

14% Upside

Fisher & Paykel Healthcare Corporation Ltd

13% Downside

Beijing Wandong Medical Technology Co Ltd

5% Downside

Shanghai United Imaging Healthcare Co Ltd

18% Upside

SWS Hemodialysis Care Co Ltd

25% Upside

Lifecare AS

50% Upside

Imricor Medical Systems Inc

96% Upside

Nanalysis Scientific Corp

178% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Penumbra Inc's revenue is 24%. The projected CAGR for the next 3 years is 17%.

24%

17%

0%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Penumbra Inc's operating income is 47%. The projected CAGR for the next 3 years is 42%.

47%

42%

-45%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Penumbra Inc's net income is 74%. The projected CAGR for the next 3 years is 31%.

74%

31%

13%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for PEN is 282.93 USD with a low forecast of 242.4 USD and a high forecast of 336 USD.

For the last 8 years the compound annual growth rate for Penumbra Inc's revenue is 24%. The projected CAGR for the next 3 years is 17%.

For the last 8 years the compound annual growth rate for Penumbra Inc's operating income is 47%. The projected CAGR for the next 3 years is 42%.

For the last 8 years the compound annual growth rate for Penumbra Inc's net income is 74%. The projected CAGR for the next 3 years is 31%.

Join more than 134,600+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.